|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: CCPG1 |
Gene summary for CCPG1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | CCPG1 | Gene ID | 9236 |
| Gene name | cell cycle progression 1 | |
| Gene Alias | CPR8 | |
| Cytomap | 15q21.3 | |
| Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | Q9ULG6 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 9236 | CCPG1 | LZE4T | Human | Esophagus | ESCC | 9.27e-15 | 4.20e-01 | 0.0811 |
| 9236 | CCPG1 | LZE5T | Human | Esophagus | ESCC | 1.29e-04 | 6.96e-01 | 0.0514 |
| 9236 | CCPG1 | LZE7T | Human | Esophagus | ESCC | 1.29e-06 | 5.02e-01 | 0.0667 |
| 9236 | CCPG1 | LZE8T | Human | Esophagus | ESCC | 1.70e-11 | 3.24e-01 | 0.067 |
| 9236 | CCPG1 | LZE22T | Human | Esophagus | ESCC | 4.79e-04 | 3.01e-01 | 0.068 |
| 9236 | CCPG1 | LZE24T | Human | Esophagus | ESCC | 1.44e-05 | 3.11e-01 | 0.0596 |
| 9236 | CCPG1 | LZE6T | Human | Esophagus | ESCC | 7.02e-08 | 3.35e-01 | 0.0845 |
| 9236 | CCPG1 | P1T-E | Human | Esophagus | ESCC | 6.70e-07 | 5.66e-01 | 0.0875 |
| 9236 | CCPG1 | P2T-E | Human | Esophagus | ESCC | 7.73e-17 | 2.47e-01 | 0.1177 |
| 9236 | CCPG1 | P4T-E | Human | Esophagus | ESCC | 3.26e-13 | 4.41e-01 | 0.1323 |
| 9236 | CCPG1 | P5T-E | Human | Esophagus | ESCC | 9.03e-16 | 3.79e-01 | 0.1327 |
| 9236 | CCPG1 | P8T-E | Human | Esophagus | ESCC | 4.08e-49 | 1.01e+00 | 0.0889 |
| 9236 | CCPG1 | P9T-E | Human | Esophagus | ESCC | 3.00e-13 | 4.44e-01 | 0.1131 |
| 9236 | CCPG1 | P10T-E | Human | Esophagus | ESCC | 5.45e-10 | 2.07e-01 | 0.116 |
| 9236 | CCPG1 | P11T-E | Human | Esophagus | ESCC | 6.20e-17 | 7.16e-01 | 0.1426 |
| 9236 | CCPG1 | P12T-E | Human | Esophagus | ESCC | 4.26e-15 | 3.45e-01 | 0.1122 |
| 9236 | CCPG1 | P15T-E | Human | Esophagus | ESCC | 3.26e-05 | 2.74e-01 | 0.1149 |
| 9236 | CCPG1 | P16T-E | Human | Esophagus | ESCC | 3.29e-09 | 2.11e-01 | 0.1153 |
| 9236 | CCPG1 | P19T-E | Human | Esophagus | ESCC | 8.33e-05 | 7.29e-01 | 0.1662 |
| 9236 | CCPG1 | P20T-E | Human | Esophagus | ESCC | 2.44e-07 | 1.88e-01 | 0.1124 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0051098111 | Esophagus | ESCC | regulation of binding | 251/8552 | 363/18723 | 6.73e-20 | 8.46e-18 | 251 |
| GO:004578710 | Esophagus | ESCC | positive regulation of cell cycle | 196/8552 | 313/18723 | 9.27e-10 | 2.24e-08 | 196 |
| GO:004308715 | Esophagus | ESCC | regulation of GTPase activity | 183/8552 | 348/18723 | 5.34e-03 | 2.00e-02 | 183 |
| GO:005109812 | Liver | Cirrhotic | regulation of binding | 148/4634 | 363/18723 | 9.14e-12 | 5.97e-10 | 148 |
| GO:00457874 | Liver | Cirrhotic | positive regulation of cell cycle | 97/4634 | 313/18723 | 6.88e-03 | 3.38e-02 | 97 |
| GO:005109822 | Liver | HCC | regulation of binding | 225/7958 | 363/18723 | 3.78e-14 | 2.37e-12 | 225 |
| GO:004578711 | Liver | HCC | positive regulation of cell cycle | 172/7958 | 313/18723 | 5.29e-06 | 6.58e-05 | 172 |
| GO:005109820 | Oral cavity | OSCC | regulation of binding | 212/7305 | 363/18723 | 3.88e-14 | 2.15e-12 | 212 |
| GO:00457879 | Oral cavity | OSCC | positive regulation of cell cycle | 173/7305 | 313/18723 | 3.28e-09 | 7.44e-08 | 173 |
| GO:004308710 | Oral cavity | OSCC | regulation of GTPase activity | 165/7305 | 348/18723 | 7.94e-04 | 4.27e-03 | 165 |
| GO:005109819 | Prostate | Tumor | regulation of binding | 122/3246 | 363/18723 | 2.86e-14 | 3.63e-12 | 122 |
| GO:004578714 | Prostate | Tumor | positive regulation of cell cycle | 81/3246 | 313/18723 | 8.45e-05 | 8.46e-04 | 81 |
| GO:004308713 | Prostate | Tumor | regulation of GTPase activity | 88/3246 | 348/18723 | 1.04e-04 | 1.00e-03 | 88 |
| GO:0051098113 | Thyroid | PTC | regulation of binding | 195/5968 | 363/18723 | 3.21e-18 | 3.37e-16 | 195 |
| GO:004578718 | Thyroid | PTC | positive regulation of cell cycle | 144/5968 | 313/18723 | 9.93e-08 | 1.99e-06 | 144 |
| GO:004308718 | Thyroid | PTC | regulation of GTPase activity | 148/5968 | 348/18723 | 1.63e-05 | 1.71e-04 | 148 |
| GO:1904424 | Thyroid | PTC | regulation of GTP binding | 11/5968 | 15/18723 | 1.19e-03 | 6.84e-03 | 11 |
| GO:005109834 | Thyroid | ATC | regulation of binding | 203/6293 | 363/18723 | 1.18e-18 | 1.55e-16 | 203 |
| GO:004578719 | Thyroid | ATC | positive regulation of cell cycle | 158/6293 | 313/18723 | 4.18e-10 | 1.14e-08 | 158 |
| GO:004308719 | Thyroid | ATC | regulation of GTPase activity | 153/6293 | 348/18723 | 3.24e-05 | 2.68e-04 | 153 |
| Page: 1 2 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| CCPG1 | SNV | Missense_Mutation | c.419C>G | p.Ser140Cys | p.S140C | Q9ULG6 | protein_coding | tolerated(0.17) | probably_damaging(0.974) | TCGA-A1-A0SI-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| CCPG1 | SNV | Missense_Mutation | c.1321G>A | p.Glu441Lys | p.E441K | Q9ULG6 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| CCPG1 | SNV | Missense_Mutation | c.357T>G | p.Asn119Lys | p.N119K | Q9ULG6 | protein_coding | tolerated(0.59) | benign(0.019) | TCGA-D8-A1JM-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | ChemotherapyHormone Therapy | doxorubicine | SD | |
| CCPG1 | SNV | Missense_Mutation | c.91N>T | p.Thr31Ser | p.T31S | Q9ULG6 | protein_coding | tolerated(0.36) | benign(0.018) | TCGA-E9-A24A-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD | |
| CCPG1 | SNV | Missense_Mutation | c.536N>A | p.Arg179His | p.R179H | Q9ULG6 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-E9-A5FL-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| CCPG1 | insertion | Frame_Shift_Ins | novel | c.836_837insCTCAGAAAACGAACCTTGCTAC | p.Lys279AsnfsTer19 | p.K279Nfs*19 | Q9ULG6 | protein_coding | TCGA-A2-A0T2-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | xeloda | PD | ||
| CCPG1 | insertion | Frame_Shift_Ins | novel | c.1931_1932insAATCCTTATCTTAGGGATACTTGAACACAAACACTGTGGTAGGA | p.Phe644LeufsTer20 | p.F644Lfs*20 | Q9ULG6 | protein_coding | TCGA-AR-A0TY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | PD | ||
| CCPG1 | SNV | Missense_Mutation | c.121N>A | p.Glu41Lys | p.E41K | Q9ULG6 | protein_coding | deleterious(0.04) | possibly_damaging(0.773) | TCGA-C5-A7CL-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | PD | |
| CCPG1 | SNV | Missense_Mutation | c.563C>T | p.Ser188Leu | p.S188L | Q9ULG6 | protein_coding | deleterious(0.02) | probably_damaging(0.952) | TCGA-DR-A0ZM-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unspecific | Cisplatin | SD | |
| CCPG1 | SNV | Missense_Mutation | c.1183G>T | p.Ala395Ser | p.A395S | Q9ULG6 | protein_coding | tolerated(0.21) | benign(0.432) | TCGA-DS-A0VM-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD |
| Page: 1 2 3 4 5 6 7 8 9 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |